换一批
换一批Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
第一作者：
F,Millot
第一单位：
Department of Pediatrics, University Hospital of Poitiers, France. f.millot@chu-poitiers.fr
作者：
主题词
保险统计分析(Actuarial Analysis);青少年(Adolescent);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);天冬酰胺酶(Asparaginase);中枢神经系统(Central Nervous System);儿童(Child);儿童, 学龄前(Child, Preschool);阿糖胞苷(Cytarabine);柔红霉素(Daunorubicin);无病生存(Disease-Free Survival);药物协同作用(Drug Synergism);欧洲(Europe);女(雌)性(Female);人类(Humans);婴儿(Infant);婴儿, 新生(Infant, Newborn);输注, 静脉内(Infusions, Intravenous);注射, 脊髓(Injections, Spinal);白血病浸润(Leukemic Infiltration);男(雄)性(Male);甲氨蝶呤(Methotrexate);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);泼尼松(Prednisone);回归分析(Regression Analysis);危险(Risk);长春新碱(Vincristine)
DOI
10.1200/JCO.2001.19.7.1935
PMID
11283125
发布时间
2017-02-10
- 浏览28
Journal of clinical oncology
1935-42页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
